Transatlantic commercial agreement set to increase use of rapid mHealth technology

Abingdon Health and DCN Diagnostics have announced a commercial partnership to provide Abingdon Health's proprietary AppDx Smartphone m-Health technology to DCN Diagnostics' customer base.
 
YORK, U.K. - April 2, 2020 - PRLog -- Under the terms of the agreement, the companies will work together to provide DCN Dx's customers with lateral flow testing solutions that incorporate Abingdon Health's Smartphone AppDx technology.

AppDx is cutting-edge mHealth software that turns a Smartphone into a lateral flow reader. By utilising cameras and connectivity within smartphones, AppDx enables rapid test results to be captured and presented locally to the user or cloud connected to stakeholders directly through a data portal. AppDx's provision of lab-quality results in any location creates flexible testing solutions and allows real-time health monitoring and management.

Chris Yates, CEO, of Abingdon Health:

"We are delighted to partner with DCN Diagnostics. We believe our AppDX technology has an important role to play in the decentralization of rapid testing, and DCN Diagnostics is a great partner to support the roll-out of our recently launched technology.

Brendan O'Farrell, President and Founding Partner of DCN Diagnostics:

Comment and full post can be found here: https://www.abingdonhealth.com/abingdon-health-and-dcn-diagnostics-partner-on-commercialisation-of-appdx-m-health-technology/
End
Email:***@abingdonhealth.com Email Verified
Tags:Rapid Testing
Industry:Science
Location:York - Yorkshire - England
Subject:Partnerships
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Abingdon Health PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share